New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 4, 2014
12:09 EDTPBPB, AMTD, GRUB, SNX, ETFC, MYL, HALOOn The Fly: Midday Wrap
Stocks on Wall Street were lower at midday despite the government reporting that employers added 192K jobs in March and hired more in January and February than previously thought. The Nasdaq, which has been leading the equity indexes higher since the beginning of the year, is today's leader to the downside. While the Dow and S&P were down fractionally near noon, the Nasdaq was down about 2%. ECONOMIC EVENTS: In the U.S., the Department of Labor's monthly jobs report showed nonfarm payrolls increased 192K in March, versus the consensus forecast for 200K job additions. Notably, February's job gain was revised up to 197K from the prior estimate of 175K and January war revised up to 144K from 129K. The unemployment rate in March was steady at 6.7%. COMPANY NEWS: Shares of drugmaker Mylan (MYL) were up by a double-digit percentage in pre-market trading following a Financial Times report of the company's desire to buy Swedish rival Meda. Subsequent to the story being published, Meda confirmed it had been in talks with Mylan but rejected the company's takeover offer. Despite the rejection, Mylan shares remained up about 4% near midday... Four new stocks made their debuts on the New York Stock Exchange and Nasdaq this morning, highlighted by the initial public offering of food delivery service GrubHub (GRUB). GrubHub, which had priced its offering of 7.41M shares at $26.00, opened for trade at $40.00 per share. MAJOR MOVERS: Among the notable gainers was SYNNEX (SNX), which rallied 22% after the company’s first quarter results and second quarter outlook topped analysts’ consensus estimates. Also higher were shares of sandwich shop owner Potbelly (PBPB), which rose almost 6% after its stock was upgraded to Outperform at William Blair. Among the noteworthy losers was Halozyme (HALO), which dropped 29% after an independent committee recommended it temporarily halt patient enrollment and dosing of a Phase 2 trial evaluating a drug in patients with pancreatic cancer. Also lower for a second straight day were shares of brokerage firms E-Trade (ETFC) and TD Ameritrade (AMTD) amid concerns that regulators will look to eliminate one of the companies' more profitable businesses amid a growing furor over high-frequency trading sparked by Michael Lewis' new book "Flash Boys." INDEXES: Near midday, the Dow was down 34.07, or 0.21%, to 16,538.48, the Nasdaq was down 85.13, or 2.01%, to 4,152.61, and the S&P 500 was down 9.66, or 0.51%, to 1,879.11.
News For MYL;GRUB;PBPB;ETFC;AMTD;HALO;SNX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
July 24, 2015
06:49 EDTETFCE-Trade says NY Fed eases company oversight, Reuters says
E-Trade said that the New York Federal Reserve has relaxed its oversight of the company during the second quarter, giving the company more latitude to make strategic decisions about its future, Reuters reports. "It moves us to a different footing with regulators on how quickly we can move to do things," CEO Paul Idzik said on an analysts' call Thursday evening after the company reported Q2 earnings. "The dialogue has shifted." Reference Link
July 23, 2015
18:01 EDTETFCE-Trade reports Q2 DARTs of 149K
Subscribe for More Information
16:22 EDTETFCE-Trade reports Q EPS 25c, consensus 27c
Subscribe for More Information
09:04 EDTMYLTeva says 'strongly disagrees' with Stichting stated analysis
Teva Pharmaceutical Industries (TEVA) issued the following statement regarding Stichting Preferred Shares Mylan’s (MYL) decision to exercise its call option: "We strongly disagree with the stated analysis of Stichting Preferred Shares Mylan and its decision to exercise its call option, which is unwarranted, relies on false assumptions, and risks depriving Mylan stockholders and other stakeholders of the value inherent in a combination of Teva and Mylan. We continue to believe that our proposed transaction offers a compelling opportunity for value-creation and many other benefits for the stockholders, customers, patients, and employees of both companies. We are well advised on Dutch law, including the ability of Mylan stockholders to challenge this action in court, and are prepared to take the necessary actions at the appropriate time."
08:48 EDTMYLMylan, Teva lower after Stitching looks to thwart hostile deal
Subscribe for More Information
08:48 EDTMYLMylan confirms exercise of full call option by independent foundation
Subscribe for More Information
08:34 EDTMYLMylan foundation exercises call option to 'level playing field'
08:33 EDTMYLMylan foundation says shareholders at risk of Teva takeover
Subscribe for More Information
July 22, 2015
11:30 EDTSNXNew Age Electronics announces distribution agreement with KEF
Subscribe for More Information
10:06 EDTMYLAbbott CEO says supportive of Mylan pursuit of Perrigo
Subscribe for More Information
10:01 EDTAMTDOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
09:30 EDTMYLAbbott CEO says 'pretty alligned' with Mylan so far
07:37 EDTAMTDTD Ameritrade downgraded to Sell from Neutral at Citi
Subscribe for More Information
July 21, 2015
07:48 EDTGRUBGrubHub weakness a buying opportunity, says Brean Capital
Subscribe for More Information
07:33 EDTAMTDTD Ameritrade CEO: Company 'upbeat' about growth, prospects
Subscribe for More Information
07:32 EDTAMTDTD Ameritrade reports Q3 EPS 36c, consensus 36c
Subscribe for More Information
July 20, 2015
15:01 EDTAMTDNotable companies reporting before tomorrow's open
Subscribe for More Information
08:38 EDTMYLAnalyst predicts Zoetis merges with Bayer unit, not Valeant
Zoetis (ZTS) in recent months has been the subject of takeover speculation, possibly for Valeant (VRX), but a Jefferies analyst told investors today in a research note that he views a deal with a unit of healthcare giant Bayer (BAYRY) as "highly likely" for the animal medicine company. BACKGROUND: Bill Ackman of Pershing Square, who owns stakes in both Zoetis and Valeant, said in early May while speaking on CNBC that Zoetis is a "great” business on a standalone basis, but he also spoke of the company's strategic value. Ackman added, however, that he was "not sure" that Valeant was the best acquirer of Zoetis. Subsequently, in late June, The Wall Street Journal reported that Valeant made a preliminary approach regarding a potential deal to buy Zoetis. CNBC's David Faber said the next day, citing his own sources, that Valeant reached out to Zoetis as a courtesy to common shareholder Ackman and was unlikely to pursue an acquisition of the company, though he cautioned then Valeant could change its approach and pursue a deal. BAYER: Jefferies analyst Jeffrey Holford said in a note today that he views a tie-up between Zoetis and Bayer's Animal Health business in 2016 as "highly likely." He sees Mylan's (MYL) acquisition of Abbott's (ABT) non‑U.S. developed markets specialty and branded generics business as a potential proxy for how a transaction could be structured, adding that such a "spinversion" could achieve up to 36% long-term earnings accretion for Zoetis. Holford reiterated a Buy rating on Zoetis with a $60 price target, while downgrading Bayer to Hold, citing valuation following the recent outperformance of its shares. IDEXX: While being discussed as a target, some analysts have also opined on companies that Zoetis could pursue as a buyer. On June 29, Canaccord said that in investor meetings with IDEXX (IDXX) executives declined to comment on Zoetis' potential interest in scaling up its animal health diagnostics business. Canaccord added that it thought Zoetis could make a bid for IDEXX. The firm reiterated its Buy rating and $80 price target on IDEXX shares at that time. PRICE ACTION: Since June 25, the day the Journal first reported on Valeant's preliminary takeover approach to Zoetis, the animal health company's shares have dropped nearly 4%. Zoetis closed down 20c to $47.80 on Friday.
07:33 EDTMYLInternational AIDS Society to hold a conference
Subscribe for More Information
07:30 EDTMYLZoetis 'highly likely' to merge with Bayer unit in 2016, says Jefferies
Subscribe for More Information
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use